AGPAT4-IT1

Summary

AGPAT4-IT1 (AGPAT4 intronic transcript 1, HGNC:20988) is a long non-coding RNA gene on chromosome 6q26.

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20988
Approved symbol	AGPAT4-IT1
Name	AGPAT4 intronic transcript 1
Location	6q26
Locus type	RNA, long non-coding
Status	Approved
Aliases	FLJ23112
Entrez	79992
RNAcentral	URS000075D301 — lncRNA, 1869 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Putative uncharacterized protein encoded by AGPAT4-IT1 — Q9H0P7 (reviewed: Q9H0P7)

Alternative names: AGPAT4 intronic transcript 1

All UniProt accessions (0):

UniProt curated annotations — full annotation on UniProt →

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

UniProt features (2 total): chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H0P7-F1	35.71	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0A096LPI5, A0A0A0MT76, A4D1N5, A6NM66, A8MUN3, B1ANH7, F5HDA4, O76042, P03414, P04219, P06831, P0C092, P0C5K7, P0C7Q2, P15099, P37125, P37200, P49671, Q1W209, Q21QM3, Q2M3A8, Q4G0G2, Q5T0J3, Q5T6R2, Q5T742, Q5TEZ4, Q5VSD8, Q5W150, Q6UXP9, Q6W349, Q6ZP68, Q6ZS52, Q6ZSR6, Q6ZV60, Q6ZVU0, Q8IWL8, Q8N6C7, Q8N814, Q8TCH9, Q8TEV8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000035192 (6:161162074 A>G), RS1001646803 (6:161163336 G>C), RS1001708742 (6:161163015 T>C), RS1002832032 (6:161160825 G>A), RS1003884408 (6:161161714 G>A,C), RS1003915942 (6:161160163 T>C), RS1004836756 (6:161162924 C>A), RS1004905708 (6:161161976 T>C), RS1004977313 (6:161163693 G>C), RS1005575314 (6:161162554 G>C), RS1007142055 (6:161160064 A>C,G), RS1008265807 (6:161161358 T>C), RS1008405497 (6:161161417 T>A,C), RS1009541906 (6:161160886 C>T), RS1009656494 (6:161160612 C>A,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Particulate Matter	affects expression, decreases expression	2
propionaldehyde	increases expression	1
bisphenol A	affects cotreatment, decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Acetaminophen	increases expression	1
Atrazine	decreases expression	1
Benzene	increases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Propofol	decreases expression	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.